Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M

Surrozen, Inc./DE

2024-Q2 EPS reported -$13.00

Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.
Net loss $25.3M vs $9.4M in Q2 2023; includes $20.4M loss on issuance of pre-funded warrants and warrants.
R&D expenses decreased to $5.3M from $6.9M YoY, reflecting 2023 restructuring.
Phase 1b trial of SZN-043 for severe alcoholic hepatitis ongoing; proof-of-concept data expected H1 2025.
Boehringer Ingelheim partnership for SZN-413 may trigger $10M milestone if lead candidate nominated in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.